PROGNOSTIC FACTORS IN HUMAN PRIMARY BREAST-CANCER - COMPARISON OF C-MYC AND HER2/NEU AMPLIFICATION

被引：42

作者：

BERNS, EMJJ ^{[1
]}

FOEKENS, JA ^{[1
]}

VANPUTTEN, WLJ ^{[1
]}

VANSTAVEREN, IL ^{[1
]}

PORTENGEN, H ^{[1
]}

DEKONING, WCH ^{[1
]}

KLIJN, JGM ^{[1
]}

机构：

[1] DR DANIEL DEN HOED CANC CTR, DEPT MED ONCOL, DIV ENDOCRINE ONCOL, POB 5201, 3008 AE ROTTERDAM, NETHERLANDS

来源：

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY | 1992年 / 43卷 / 1-3期

关键词：

D O I：

10.1016/0960-0760(92)90182-I

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Amplification of oncogenes in primary tumours may have prognostic and/or therapeutic significance for patients with breast cancer. We have studied HER2/neu and c-myc amplification together with steroid receptors in human primary breast tumours and related the outcome with (relapse-free) survival. A strong inverse correlation was found between HER2/neu amplification and the presence of oestrogen and progesterone receptors. Actuarial 5-years survival showed that breast cancer patients with c-myc amplification in their primary tumours experience a shorter relapse-free survival, especially in node-negative and in receptor-positive tumours, whereas HER2/neu amplification may be of prognostic value for overall survival in receptor-negative tumours. Overall, in our hands, c-myc amplification appeared to be a more potent prognosticator than HER2/neu amplification in human primary breast cancer.

引用

页码：13 / 19

页数：7

共 76 条

[41] LOSS OF HETEROZYGOSITY IN HUMAN DUCTAL BREAST-TUMORS INDICATES A RECESSIVE MUTATION ON CHROMOSOME-13 [J].